Nifty Pharma Index: Price, Performance, and Sector Drivers Today
The Nifty Pharma Index (Ticker: NIFTYPHARMA) tracks the performance of major pharmaceutical companies listed on the National Stock Exchange (NSE). The index is highly sensitive to regulatory changes in the US and Indian markets, R&D successes, currency fluctuations (USD/INR), and domestic healthcare spending.
Nifty Pharma Share Price Today
The Nifty Pharma Index closed with marginal gains today, largely consolidating its position after a period of volatility. Performance was mixed, with gains in domestic-focused players offsetting losses in certain export-heavy companies.
| Metric |
Value (As of Nov 26, 2025 Close) |
Change |
| Closing Value |
17,542.80 (Approx.) |
+10.15 points (≈+0.06%) |
| Previous Close |
17,532.65 |
- |
| Day's Range (Low - High) |
17,478.40 - 17,615.95 |
- |
| 52 Week High / Low |
18,367.50 / 13,018.60 |
- |
| P/E Ratio (TTM) |
≈31.5 |
- |
Export to Sheets
Nifty Pharma Index Historical Returns
The sector has recently outperformed the broader market, driven by stable revenue from regulated markets and a strong rebound in the Indian domestic formulation market.
| Period |
Absolute Return (Approximate) |
Key Trend |
| 1 Month |
≈+4.10% |
Indicates strong short-term upward momentum. |
| 1 Year |
≈+15.95% |
Significant outperformance relative to the Nifty 50. |
| 3 Years |
≈+45.28% |
Strong compounding returns, reflecting sectoral stability. |
Export to Sheets
Nifty Pharma Stocks List (Top Constituents by Weightage)
The Nifty Pharma Index is composed of 20 companies and is quite concentrated, with the top few stocks largely determining the index's direction.
| Company Name |
Ticker Symbol |
Key Focus Area |
Approximate Index Weightage* |
| Sun Pharmaceutical Industries Ltd |
SUNPHARMA |
Generics, Specialty (US, India) |
≈22.18% |
| Dr. Reddy's Laboratories Ltd |
DRREDDY |
Generics, APIs (US, India) |
≈10.95% |
| Cipla Ltd |
CIPLA |
Generics, Respiratory (India, Emerging Mkts) |
≈10.42% |
| Divi's Laboratories Ltd |
DIVISLAB |
Custom Synthesis, APIs |
≈9.77% |
| Lupin Ltd |
LUPIN |
Generics (US, India) |
≈8.41% |
| Aurobindo Pharma Ltd |
AUROPHARMA |
Generics (US) |
≈5.75% |
| Zydus Lifesciences Ltd |
ZYDUSLIFE |
Generics, Vaccines (India, US) |
≈4.88% |
Export to Sheets
Key Drivers for Nifty Pharma Performance
-
US Generic Pricing: The primary challenge has been margin pressure in the US generic market. However, recent stabilization and approval of new, high-value specialty products by major players have provided tailwinds.
-
USD/INR Exchange Rate: Since most companies in the Nifty Pharma stocks list earn a significant portion of their revenue in US Dollars, a weakening Rupee (higher USD/INR) boosts their profits and is a positive catalyst for the index.
-
Domestic Growth: The Indian domestic market remains a stable growth driver, supported by increasing healthcare spending and the launch of new products. Companies with a strong India focus (like Cipla, Zydus) tend to benefit from this stability.
-
USFDA Compliance: Successful resolution of US Food and Drug Administration (USFDA) issues at manufacturing plants is a major positive trigger, while any adverse observation can lead to sharp drops in stock prices.